Sientra (SIEN) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sientra stock.
View analyst ratings for Sientra or view top-rated stocks.

6 Wall Street analysts have issued 12 month target prices for Sientra's stock. Their SIEN stock forecasts range from $5.00 to $10.00. On average, they expect Sientra's share price to reach $7.29 in the next year. This suggests a possible upside of 424.2% from the stock's current price.
View analysts' price targets for Sientra or view top-rated stocks among Wall Street analysts.

Sientra's stock was trading at $3.67 at the beginning of the year. Since then, SIEN stock has decreased by 62.1% and is now trading at $1.39.
View the best growth stocks for 2022 here.

Sientra is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Sientra.

Sientra will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Sientra, Inc. (NASDAQ:SIEN) posted its quarterly earnings data on Thursday, May, 12th. The medical instruments supplier reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.03. The medical instruments supplier earned $21.40 million during the quarter, compared to analysts' expectations of $20.25 million. Sientra had a negative net margin of 71.61% and a negative trailing twelve-month return on equity of 498.54%.

Sientra updated its FY 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $93.00 million-$97.00 million, compared to the consensus revenue estimate of $95.00 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Rigel Pharmaceuticals (RIGL), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Micron Technology (MU) and Novavax (NVAX).

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Sientra's stock is owned by many different institutional and retail investors. Top institutional shareholders include Granite Point Capital Management L.P. (2.86%) and Stephens Inc. AR (0.08%). Company insiders that own Sientra stock include Andrew C Schmidt, Andrew C Schmidt, Hove Caroline F Van, Jeffrey M Nugent, Oliver Christian Bennett, Paul Sean Little, Ronald Menezes and Valerie J Miller.
View institutional ownership trends for Sientra.

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SIEN stock can currently be purchased for approximately $1.39.

Sientra (NASDAQ:SIEN) has a market capitalization of $87.07 million and generates $80.68 million in revenue each year. The medical instruments supplier earns $-62,480,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

Sientra employs 319 workers across the globe.

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The official website for Sientra is www.sientra.com. The medical instruments supplier can be reached via phone at (805) 562-3500, via email at ir@sientra.com, or via fax at 805-562-8401.